JPMorgan analyst Chris Schott raised the firm’s price target on Gilead (GILD) to $150 from $145 and keeps an Overweight rating on the shares post the Q3 report. The firm says the Yeztugo launch is off to an “encouraging start.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strong Q3 2025 Performance and Growth Potential Justify Buy Rating
- Gilead price target raised to $145 from $140 at Wells Fargo
- Gilead Sciences Reports Strong Q3 2025 Results
- Gilead Sciences: Strong Financial Performance and Promising Growth Prospects Justify Buy Rating
- Closing Bell Movers: Amazon soars to all-time highs on earnings